news

news

    • Jun Sasaki, President and CEO of Rena Therapeutics Inc. made a presentation at “Nucleic Acids Therapeutics Society of Japan” held in Kyushu.
      July 9, 2018
    • Jun Sasaki, President and CEO of Rena Therapeutics Inc. gives a presentation at Network Night” held by INCJ.
      May 10, 2018
    • Exhibited the panel at INCJ booth in BioJapan2017 held in PACIFICO Yokohama for introducing our business and technology
      October 11-13, 2017
  • Participated in 3rd Annual Meeting of the Nucleic Acids Therapeutics Society of Japan in Hokkaido
    July 12-14, 2017
  • Announcement on Completion of Issue of New Shares through Third-Party Allotment
    June 30, 2017
  • Participated in BIO International Convention 2017 in San Diego, California
    June 19-22, 2017
  • Our platform Hetero-Duplex Oligonucleotide Technology’s basic patent was registered in Japan(Patent No.JP6112569)
    March 24, 2017
  • Made a presentation at “BioAsia2017” held in Roppongi Tokyo, co-hosted by BioCentury and JBA(Japan Bioindustry Association)
    March 15, 2017
  • Made a presentation at “Biotechnology-related industry matching meeting & presentation at Nihonbashi” hosted by Kanto Bureau of Economy, Trade and Industry, METI
    January 26, 2017
  • Rena Therapeutics Inc. marked the second anniversary
    January 15, 2017
  • Junichi Yano was appointed Chairman, and Jun Sasaki was appointed President & CEO
    December 15, 2016
  • Exhibited the panel at INCJ booth in BioJapan2016 held in PACIFICO Yokohama for introducing our business and technology
    October 12-14, 2016
  • Press conference
    August 7, 2015
  • Series A funding from Innovation Network Corporation of Japan, DBJ Capital Co., Ltd. and KSP Inc. is completed
    April 20, 2015
  • Granted university ventures honor from Tokyo Medical and Dental University
    February 25, 2015
  • Rena Therapeutics Inc. founded
    January 15, 2015